OBJECTIVES: To examine interactions among clinical factors and pathologic biomarkers in predicting the outcome of patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy. METHODS: In 85 patients treated at a single institution, clinicopathologic variables were analyzed, including the International Prognostic Index (IPI); germinal/nongerminal center phenotype; MYC, p53, BCL2, Ki-67, and Epstein-Barr virus (EBV) expression; and MYC translocation status. RESULTS: In univariate analysis, overall survival (OS) was worse for patients with high IPI scores, nongerminal center phenotype, high MYC and p53 expression by immunohistochemistry, and EBV positivity. In multivariable analysis, p53 expression was the strongest prognostic factor (P < .05) independent of IPI and cell of origin. A significant positive association between p53 and MYC expression was found. Moreover, coexpression of p53/MYC had an enhanced negative effect on OS independent of BCL2 expression. CONCLUSIONS: Immunohistochemical assessment of p53, particularly in combination with MYC, could be useful in identifying a high-risk subgroup of DLBCL.
OBJECTIVES: To examine interactions among clinical factors and pathologic biomarkers in predicting the outcome of patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy. METHODS: In 85 patients treated at a single institution, clinicopathologic variables were analyzed, including the International Prognostic Index (IPI); germinal/nongerminal center phenotype; MYC, p53, BCL2, Ki-67, and Epstein-Barr virus (EBV) expression; and MYC translocation status. RESULTS: In univariate analysis, overall survival (OS) was worse for patients with high IPI scores, nongerminal center phenotype, high MYC and p53 expression by immunohistochemistry, and EBV positivity. In multivariable analysis, p53 expression was the strongest prognostic factor (P < .05) independent of IPI and cell of origin. A significant positive association between p53 and MYC expression was found. Moreover, coexpression of p53/MYC had an enhanced negative effect on OS independent of BCL2 expression. CONCLUSIONS: Immunohistochemical assessment of p53, particularly in combination with MYC, could be useful in identifying a high-risk subgroup of DLBCL.
Entities:
Keywords:
Diffuse large B-cell lymphoma; MYC immunohistochemistry; P53 immunohistochemistry
Authors: Xuan J Wang; Carlos E Bueso-Ramos; Guilin Tang; Sa Wang; Yasuhiro Oki; Parth Desai; Joseph D Khoury; Roberto N Miranda; Zhenya Tang; Nishitha Reddy; Shaoying Li Journal: Mod Pathol Date: 2016-10-14 Impact factor: 7.842
Authors: Elizabeth L Courville; Sophia Yohe; David Chou; Valentina Nardi; Aleksandr Lazaryan; Beenu Thakral; Andrew C Nelson; Judith A Ferry; Aliyah R Sohani Journal: Mod Pathol Date: 2016-07-22 Impact factor: 7.842
Authors: Manman Deng; Zijun Y Xu-Monette; Lan V Pham; Xudong Wang; Alexandar Tzankov; Xiaosheng Fang; Feng Zhu; Carlo Visco; Govind Bhagat; Karen Dybkaer; April Chiu; Wayne Tam; Youli Zu; Eric D Hsi; Hua You; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Benjamin M Parsons; Fredrick Hagemeister; J Han van Krieken; Miguel A Piris; Jane N Winter; Yong Li; Bing Xu; Phillip Liu; Ken H Young Journal: Mol Cancer Res Date: 2020-11-05 Impact factor: 6.333
Authors: Ana-Iris Schiefer; Christoph Kornauth; Ingrid Simonitsch-Klupp; Cathrin Skrabs; Eva Katharina Masel; Berthold Streubel; Katrina Vanura; Karin Walter; Brigitta Migschitz; Dagmar Stoiber; Veronika Sexl; Markus Raderer; Andreas Chott; Maria Gomes da Silva; Jose Cabecadas; Leonhard Müllauer; Ulrich Jäger; Edit Porpaczy Journal: Medicine (Baltimore) Date: 2015-12 Impact factor: 1.817